Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
出版年份 2020 全文链接
标题
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
作者
关键词
-
出版物
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-07-27
DOI
10.1186/s13045-020-00924-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs
- (2020) Rishi R. Shah et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs
- (2020) Marco De Dominici et al. BLOOD
- Proteolysis‐targeting chimeras in drug development: A safety perspective
- (2020) Kevin Moreau et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
- (2020) Olivier Mir et al. EUROPEAN JOURNAL OF CANCER
- Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance
- (2020) Ning Sun et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions
- (2020) Ahmad I. Antar et al. LEUKEMIA
- Small-molecule targeted recruitment of a nuclease to cleave an oncogenic RNA in a mouse model of metastatic cancer
- (2020) Matthew G. Costales et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- Light-induced control of protein destruction by opto-PROTAC
- (2020) Jing Liu et al. Science Advances
- PHOTACs enable optical control of protein degradation
- (2020) Martin Reynders et al. Science Advances
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors
- (2020) Dyana T. Saenz et al. BLOOD
- Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown
- (2020) Yu-Hui Jin et al. JOURNAL OF MEDICINAL CHEMISTRY
- How We Think about Targeting RNA with Small Molecules
- (2020) Matthew G. Costales et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
- (2020) Ronen Gabizon et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Construction of a human cell landscape at single-cell level
- (2020) Xiaoping Han et al. NATURE
- PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
- (2020) Sajid Khan et al. ONCOGENE
- Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2020) Ka Yang et al. ACS Medicinal Chemistry Letters
- Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
- (2020) Yonghan He et al. Nature Communications
- Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
- (2020) Xuan Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- A novel cereblon modulator for targeted protein degradation
- (2019) Sung Ah Kim et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Developing potent PROTACs tools for selective degradation of HDAC6 protein
- (2019) Zixuan An et al. Protein & Cell
- Recent advances in the development of Mcl-1 inhibitors for cancer therapy
- (2019) Alexander W. Hird et al. PHARMACOLOGY & THERAPEUTICS
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
- (2019) Carl C. Ward et al. ACS Chemical Biology
- RUNX1 targeted therapy for AML expressing somatic or germline mutation in RUNX1
- (2019) Christopher P Mill et al. BLOOD
- BETP degradation simultaneously targets acute myelogenous leukemic stem cells and the microenvironment
- (2019) Sujan Piya et al. JOURNAL OF CLINICAL INVESTIGATION
- From Inhibition to Degradation: Targeting the Anti-apoptotic Protein Myeloid Cell Leukemia 1 (MCL1)
- (2019) James William Papatzimas et al. JOURNAL OF MEDICINAL CHEMISTRY
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix
- (2019) Benjamin R. Topacio et al. MOLECULAR CELL
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation
- (2019) George M Burslem et al. CANCER RESEARCH
- Comprehensive Integration of Single-Cell Data
- (2019) Tim Stuart et al. CELL
- Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
- (2019) Hao Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
- (2019) Jessica N. Spradlin et al. Nature Chemical Biology
- BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
- (2019) William Farnaby et al. Nature Chemical Biology
- Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
- (2019) Xiaoyu Zhang et al. Nature Chemical Biology
- Disruption of IRE1α through its kinase domain attenuates multiple myeloma
- (2019) Jonathan M. Harnoss et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma
- (2019) Neeraj Jain et al. Science Translational Medicine
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- MCL-1 inhibitors – where are we now (2019)?
- (2019) Steven Fletcher EXPERT OPINION ON THERAPEUTIC PATENTS
- Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment
- (2019) Keiko Yamakawa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders
- (2019) Shang Su et al. JOURNAL OF MEDICINAL CHEMISTRY
- Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
- (2019) Xiaotian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands
- (2019) Ziqian Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
- (2019) Patrick Pfaff et al. ACS Central Science
- Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins
- (2019) Nobumichi Ohoka et al. ACS Chemical Biology
- Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells
- (2019) Xupeng Mu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
- (2019) Longchuan Bai et al. CANCER CELL
- Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
- (2019) Thomas H. Pillow et al. ChemMedChem
- Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel–Lindau (VHL) E3 Ubiquitin Ligase
- (2019) Quanju Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Light-Induced Protein Degradation with Photocaged PROTACs
- (2019) Gang Xue et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies
- (2019) Fei Jiang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
- (2019) Peter S. Dragovich et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
- (2019) Haibin Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a first-in-class EZH2 selective degrader
- (2019) Anqi Ma et al. Nature Chemical Biology
- A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
- (2019) Sajid Khan et al. NATURE MEDICINE
- Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein–Protein Interaction Interface
- (2018) Tomoya Sameshima et al. BIOCHEMISTRY
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
- (2018) Ka Yang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Design and synthesis of novel bispecific molecules for inducing BRD4 protein degradation
- (2018) Shihui Wang et al. CHEMICAL RESEARCH IN CHINESE UNIVERSITIES
- Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chengwei Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- BCL6 as a therapeutic target for lymphoma
- (2018) Rebecca J Leeman-Neill et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation
- (2018) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
- (2018) Chelsea E. Powell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma
- (2018) Xiaohui Zhang et al. LEUKEMIA
- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
- (2018) Lara N. Gechijian et al. Nature Chemical Biology
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach
- (2018) Zuni I. Bassi et al. ACS Chemical Biology
- Homo-PROTACs for the Chemical Knockdown of Cereblon
- (2018) Christian Steinebach et al. ACS Chemical Biology
- The cutting-edge technologies of siRNA delivery and their application in clinical trials
- (2018) Kyuri Lee et al. ARCHIVES OF PHARMACAL RESEARCH
- Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
- (2018) Chung Hyo Kang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- CRISPR-Cas9 - a new addition to the drug metabolism and disposition tool box
- (2018) Maria Karlgren et al. DRUG METABOLISM AND DISPOSITION
- ZFAND5/ZNF216 is an activator of the 26S proteasome that stimulates overall protein degradation
- (2018) Donghoon Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging EZH2 Inhibitors and Their Application in Lymphoma
- (2018) Jennifer K. Lue et al. Current Hematologic Malignancy Reports
- Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
- (2018) Katherine A Donovan et al. eLife
- Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6
- (2018) William McCoull et al. ACS Chemical Biology
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
- (2018) John Hines et al. CANCER RESEARCH
- Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers
- (2018) Julien P. N. Papillon et al. JOURNAL OF MEDICINAL CHEMISTRY
- Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel–Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
- (2018) Vittoria Zoppi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
- (2018) Yangbing Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion
- (2018) George M. Burslem et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
- (2018) Nobumichi Ohoka et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
- (2017) Veronica Tisato et al. Journal of Hematology & Oncology
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
- (2017) Ian Churcher JOURNAL OF MEDICINAL CHEMISTRY
- Chemically Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals)
- (2017) Matthias Schiedel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells
- (2017) B Sun et al. LEUKEMIA
- BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment
- (2017) Georg E. Winter et al. MOLECULAR CELL
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal misfolded Blimp-1s in lymphoma cells
- (2017) Wen-Fang Wang et al. Nature Communications
- Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation
- (2017) Chiara Maniaci et al. Nature Communications
- Targeting ALK: Precision Medicine Takes on Drug Resistance
- (2017) Jessica J. Lin et al. Cancer Discovery
- Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
- (2017) Nina Kerres et al. Cell Reports
- Complex heatmaps reveal patterns and correlations in multidimensional genomic data
- (2016) Zuguang Gu et al. BIOINFORMATICS
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target
- (2016) Mariano G. Cardenas et al. CLINICAL CANCER RESEARCH
- The roles of Polycomb group proteins in hematopoietic stem cells and hematological malignancies
- (2016) Emi Takamatsu-Ichihara et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma
- (2016) Mariano G. Cardenas et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex
- (2016) Charlotte L. Sutherell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit
- (2016) Brian S. Gerstenberger et al. JOURNAL OF MEDICINAL CHEMISTRY
- A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
- (2016) Mary E. Matyskiela et al. NATURE
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls B-cell immunity through degradation of the death receptor CD95/Fas
- (2016) Sinyi Kong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Sel1L-Hrd1 Endoplasmic Reticulum-Associated Degradation Complex Manages a Key Checkpoint in B Cell Development
- (2016) Yewei Ji et al. Cell Reports
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- (2015) I. Chachoua et al. BLOOD
- Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
- (2015) C. Marty et al. BLOOD
- The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
- (2015) Bhavatarini Vangamudi et al. CANCER RESEARCH
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- WSB1 promotes tumor metastasis by inducing pVHL degradation
- (2015) Jung Jin Kim et al. GENES & DEVELOPMENT
- Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
- (2015) J Etchin et al. LEUKEMIA
- Negative Regulation of CARD11 Signaling and Lymphoma Cell Survival by the E3 Ubiquitin Ligase RNF181
- (2015) Sarah M. Pedersen et al. MOLECULAR AND CELLULAR BIOLOGY
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- HDAC inhibitors still need a home run, despite recent approval
- (2015) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
- (2015) A-S Tigan et al. ONCOGENE
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
- (2015) V Gibaja et al. ONCOGENE
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- EZH2 in normal hematopoiesis and hematological malignancies
- (2015) Laurie Herviou et al. Oncotarget
- Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
- (2014) T. Placke et al. BLOOD
- Presence of calreticulin mutations in JAK2-negative polycythemia vera
- (2014) J. Broseus et al. BLOOD
- Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities
- (2014) S Fulda LEUKEMIA
- The Neddylation-Cullin 2-RBX1 E3 Ligase Axis Targets Tumor Suppressor RhoB for Degradation in Liver Cancer
- (2014) Junfeng Xu et al. MOLECULAR & CELLULAR PROTEOMICS
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers
- (2014) G. R. Hoffman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kinase-Independent Mechanisms of Resistance of Leukemia Stem Cells to Tyrosine Kinase Inhibitors
- (2014) Christine Victoria Ichim Stem Cells Translational Medicine
- The zinc-binding region (ZBR) fragment of Emi2 can inhibit APC/C by targeting its association with the coactivator Cdc20 and UBE2C-mediated ubiquitylation
- (2014) Shisako Shoji et al. FEBS Open Bio
- Expedient Synthesis of Highly Potent Antagonists of Inhibitor of Apoptosis Proteins (IAPs) with Unique Selectivity for ML-IAP
- (2013) Mitchell Vamos et al. ACS Chemical Biology
- Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
- (2013) J. A. Woyach et al. BLOOD
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells
- (2013) Keiichiro Okuhira et al. CANCER SCIENCE
- Polycomb Repressive Complex 2 Regulates Normal Hematopoietic Stem Cell Function in a Developmental-Stage-Specific Manner
- (2013) Huafeng Xie et al. Cell Stem Cell
- Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation
- (2013) J. Shi et al. GENES & DEVELOPMENT
- FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
- (2013) Michael R. Grunwald et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Antisense battles small molecule for slice of rare lipid disorder market
- (2013) Gunjan Sinha NATURE BIOTECHNOLOGY
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The API2–MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling
- (2013) S Rosebeck et al. ONCOGENE
- Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs
- (2013) J. Hines et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
- (2012) Dennis L. Buckley et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
- (2012) Berkley E Gryder et al. Future Medicinal Chemistry
- A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
- (2012) C. Simon et al. GENES & DEVELOPMENT
- EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms
- (2012) T Ueda et al. LEUKEMIA
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- Development of target protein-selective degradation inducer for protein knockdown
- (2011) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
- (2011) A. Hamilton et al. BLOOD
- Polycomb proteins in hematologic malignancies
- (2010) D. Martin-Perez et al. BLOOD
- Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells
- (2010) I. J. Majewski et al. BLOOD
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review
- (2010) Xin An et al. LEUKEMIA RESEARCH
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Brd2disruption in mice causes severe obesity without Type 2 diabetes
- (2009) Fangnian Wang et al. BIOCHEMICAL JOURNAL
- Modes of p53 Regulation
- (2009) Jan-Philipp Kruse et al. CELL
- Double bromodomain-containing gene Brd2 is essential for embryonic development in mouse
- (2009) Enyuan Shang et al. DEVELOPMENTAL DYNAMICS
- Control of mitochondrial apoptosis by the Bcl-2 family
- (2009) J. K. Brunelle et al. JOURNAL OF CELL SCIENCE
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Chromosomal translocations: revisited yet again
- (2008) J. D. Rowley BLOOD
- Roles of unphosphorylated STATs in signaling
- (2008) Jinbo Yang et al. CELL RESEARCH
- Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications
- (2008) Xiang-Jiao Yang et al. MOLECULAR CELL
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chromosomal Abnormalities in Cancer
- (2008) Stefan Fröhling et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now